Prometheus Biosciences (RXDX) Stock Forecast, Price & News

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Prometheus Biosciences in the last year. There are currently 7 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" RXDX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RXDX, but not buy additional shares or sell existing shares.
View RXDX analyst ratings or view top-rated stocks.

11 brokers have issued 12 month price targets for Prometheus Biosciences' stock. Their RXDX share price forecasts range from $60.00 to $200.00. On average, they predict the company's stock price to reach $153.36 in the next year. This suggests that the stock has a possible downside of 22.8%.
View analysts price targets for RXDX or view top-rated stocks among Wall Street analysts.

Prometheus Biosciences' stock was trading at $110.00 on January 1st, 2023. Since then, RXDX stock has increased by 80.5% and is now trading at $198.60.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our RXDX earnings forecast.

Prometheus Biosciences, Inc. (NASDAQ:RXDX) posted its earnings results on Tuesday, May, 9th. The biopharmaceutical company reported ($0.86) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.06. The biopharmaceutical company earned $1.11 million during the quarter, compared to analyst estimates of $0.46 million. Prometheus Biosciences had a negative trailing twelve-month return on equity of 33.50% and a negative net margin of 3,768.76%. The firm's revenue was down 71.8% on a year-over-year basis.

ETFs with the largest weight of Prometheus Biosciences (NASDAQ:RXDX) stock in their portfolio include Invesco DWA Healthcare Momentum ETF (PTH), ALPS Medical Breakthroughs ETF (SBIO), Renaissance IPO ETF (IPO), Harbor Health Care ETF (MEDI), SPDR S&P Biotech ETF (XBI), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and Principal Healthcare Innovators ETF (BTEC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Prometheus Biosciences investors own include Cronos Group (CRON), Synergy Pharmaceuticals (SGYP), Immunomedics (IMMU), Freeport-McMoRan (FCX), (KITE) (KITE), La Jolla Pharmaceutical (LJPC), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD).

(RXDX) raised $126 million in an IPO on Friday, March 12th 2021. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. SVB Leerink, Credit Suisse, Stifel and Guggenheim Securities acted as the underwriters for the IPO.

Prometheus Biosciences trades on the NASDAQ under the ticker symbol "RXDX."

Prometheus Biosciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include RTW Investments LP (6.88%), BlackRock Inc. (5.89%), Fred Alger Management LLC (2.79%), Perceptive Advisors LLC (2.66%), State Street Corp (2.60%) and FMR LLC (2.41%). Insiders that own company stock include Joseph C Papa, Keith W Marshall, Mark C Mckenna, Mark Stenhouse, Perceptive Advisors Llc and Sinai Intellectual Prop Cedars.
View institutional ownership trends.

Shares of RXDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RXDX stock can currently be purchased for approximately $198.60.

Prometheus Biosciences (NASDAQ:RXDX) has a market capitalization of $9.50 billion and generates $4.00 million in revenue each year. The biopharmaceutical company earns $-141,750,000.00 in net income (profit) each year or ($3.52) on an earnings per share basis.

Prometheus Biosciences' mailing address is 4545 Towne Centre Ct, SAN DIEGO, CA 92121-1900, United States. The official website for the company is ignyta.com. The biopharmaceutical company can be reached via phone at 858-422-4300 or via email at nkurdi@prometheusbiosciences.com.